Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.
All articles by Jessica Nye, PhD
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Interrupting endocrine therapy so patients with breast cancer can attempt pregnancy does not appear to impact short-term disease outcomes.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.
Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer.
Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.
-
Latest News Your top articles for Monday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses